REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2026 May 15, 2026 All economic and financial indicators grew: Consolidated revenues of €645.0 million (€607.5 million in 2025); EBITDA of €112.0 million (€105.3 million in 2025); EBIT of €95.1 million (€88.7 million in 2025); Profit before tax amounts to €99.8 million (€86.9 million in 2025).
eClerx’s FY26 Revenue at INR 4,217.4 crore, up by 22.6%, Q4 FY26 Revenue at INR 1,135.4 crore up by 23.9% May 15, 2026 Revenue from operations rose to INR 4,117.0 crore in FY2025-26, as compared with INR 3,365.9 crore in FY2024-25, representing a 22.3% Y-o-Y growth. In U.S. dollar terms, operating revenue stood at USD 468.9 million in FY2025-26 versus USD 397.6 million in FY2024-25, representing a 17.9% Y-o-Y growth. Net profit increased to INR 706.2 crore in FY2025-26, as against INR 541.1 crore reported in FY2024-25, representing a 30.5% Y-o-Y growth.
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights May 13, 2026 FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, expected in early Q3 2026 Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028
Allianz Delivers Record Operating Profit in Strong Start to 2026 May 13, 2026 1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net [...]
De’ Longhi Group – 6.6% Growth at Constant Exchange Rates and Accelerated Net Profit: Solid Results Fully Support Guidance May 12, 2026 The Group closed another quarter with robust organic growth, driven by the excellent expansion of the professional division, with turnover growing significantly and representing 18% of the Group's total for the period, and by the positive performance of the household
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook May 12, 2026 SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 [...]
Janus Henderson Group plc Reports First Quarter 2026 Results May 8, 2026 Solid long-term investment performance, with 66%, 67%, and 68% of assets under management (“AUM”) outperforming relevant benchmarks on a three-, five-, and 10-year basis, respectively, as of March 31, 2026 AUM of US$480 billion as of March 31, 2026, an increase of 29% year over year First quarter 2026 net inflows of US$2.9 billion compared to breakeven net flows in fourth quarter 2025 First quarter 2026 diluted EPS of US$0.59 and adjusted diluted EPS of US$0.90
AngloGold Ashanti Q1 31 March 2026 Earnings Release and Dividend Declaration May 8, 2026 AngloGold Ashanti delivers record free cash flow* of $1.2bn and EBITDA*(4) of $2.3bn • Gold production(1)(2) +1% • Net cash*(4) of $868m • Q1 2026 interim dividend of $585m, or 116 cps • Proposed $2.0bn share repurchase programme announced
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
Algoma Central Corporation Reports Financial Results for the 2026 First Quarter May 7, 2026 Focused fleet growth, strategic opportunities, and built-in adaptability across domestic and international operations drove a resilient first quarter